Analysis of cytogenetic response in Ph+ chronic myeloid leukemia patients treated with interferon alpha.
- Author:
Hong HONG
1
;
Jing-Ying QIU
;
Yue-Yun LAI
;
Yan SHI
;
Qi HE
;
Hui DANG
;
Dao-Pei LU
Author Information
1. Department of Cytogenetics, Institute of Hematology and People's Hospital, Peking University, Beijing 100044, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Antineoplastic Agents;
therapeutic use;
Chromosome Aberrations;
Chromosomes, Human, Pair 22;
genetics;
Chromosomes, Human, Pair 9;
genetics;
Cytogenetic Analysis;
Female;
Humans;
Interferon-alpha;
therapeutic use;
Karyotyping;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
drug therapy;
genetics;
pathology;
Leukemia, Myeloid, Chronic-Phase;
drug therapy;
genetics;
pathology;
Male;
Middle Aged;
Retrospective Studies;
Translocation, Genetic;
Treatment Outcome
- From:
Journal of Experimental Hematology
2003;11(3):269-273
- CountryChina
- Language:Chinese
-
Abstract:
Ph chromosome occurs in nearly all patients with CML, and eliminating Ph-positive clone is a major target in the treatment of CML. IFN-alpha is a well-known effective treatment in chronic phase CML. The cytogenetic response and the prognostic factors in 128 CML patients treated with IFN-alpha were retrospectively studied. IFN-alpha administered singly at a dose of 3 million U/day for 2 - 3 times a week or in combination with either hydroxyurea (Hu), busulfan (Bu), low dose Ara-C or harringtonine. Karyotyping was examined by G-banding before and after IFN-alpha-based treatment. The results showed that all patients achieved complete hematological remission. Cytogenetic response occurred in 36 of 118 patients with standard t (9;22) translocation; 3 of these 36 patients had a complete cytogenetic response (Ph = 0), 13 had major cytogenetic responses (Ph < 35%) and 20 had minimal response (Ph > 35%). The total cytogenetic effectiveness was 13.6% (16/118). Four of seven patients with complicated variant translocation also achieved cytogenetic response, 2 of them had a major cytogenetic response and 2 had minimal response. Factors influenced the prognosis associated with cytogenetic response included sex, patient status at diagnosis and IFN-alpha administered singly or in combination with other chemotherapeutic agents. IFN-alpha could not prevent the progression of CML. It is concluded that Ph(+)CML patients with both standard and variant translocation had major cytogenetic response to IFN-alpha treatment at a dose of 6 - 9 million U/week in single or combination with Hu/Bu, however, IFN-alpha treatment could not prevent disease progression. Long term survival was also observed in patients with variant translocation treated with IFN-alpha. Regular cytogenesis examination in CML patients is necessary during IFN-alpha therapy, which is useful to reflect curative effect and progression of the disease.
